A US Food and Drug Administration advisory committee voted unanimously on June 18, 2026, that the benefits of Moderna's investigational mRNA influenza vaccine outweighed its risks for adults 50 and older. The 9-0 recommendation moved mFlusiva closer to the market, but it did not approve the vaccine.
The Vaccines and Related Biological Products Advisory Committee considered two separate regulatory questions. FDA was evaluating traditional approval for adults 50 to 64 and accelerated approval for those 65 and older, with a required post-approval trial in the older group.
The Committee Answered Two Different Questions
mFlusiva, also known as mRNA-1010, is a trivalent vaccine encoding antigens for A/H1N1, A/H3N2 and B/Victoria influenza strains. Moderna's application seeks an indication to prevent influenza disease caused by the strains represented in the seasonal vaccine.
For ages 50 to 64, FDA asked whether a randomized phase 3 efficacy trial supported traditional approval. For adults 65 and older, the agency asked whether immune-response data against Fluzone High-Dose, combined with a required phase 4 confirmatory study, supported accelerated approval.
The distinction exists because CDC preferentially recommends high-dose, recombinant or adjuvanted influenza vaccines for people 65 and older. The main efficacy trial compared mFlusiva with standard-dose licensed vaccines, so FDA separately examined a 3,003-person trial comparing immune responses with a high-dose product in that age group.
All nine advisers voted that benefits outweighed risks for each group. Advisory votes inform FDA decisions but do not bind the agency, set a vaccination recommendation or replace the product label that would accompany an approval.
The Main Trial Found Fewer Confirmed Flu Cases
The pivotal study randomly assigned more than 40,000 adults aged 50 and older to mFlusiva or a licensed standard-dose comparator. It was observer-blinded and active-controlled, and followed participants through a flu season.
In the per-protocol analysis, RT-PCR-confirmed, protocol-defined influenza-like illness occurred in 411 of 20,179 mFlusiva recipients, or 2.0%, and 557 of 20,124 comparator recipients, or 2.8%. That produced 26.6% relative vaccine efficacy over the comparator, with a 95% confidence interval from 16.7% to 35.4%.
The result means the mRNA vaccine reduced the measured outcome relative to the standard-dose vaccine used in the trial. It does not mean it prevented 26.6% of all influenza in an unvaccinated population. Both groups received an active flu vaccine, and the trial measured a defined illness confirmed by laboratory testing.
Age-subgroup estimates were directionally similar, but uncertainty was wider among participants 75 and older because there were fewer cases. FDA's briefing also noted that influenza A accounted for 94% of cases, limiting precision for influenza B.
Reactions Were More Frequent, Serious Events Were Similar
Local and systemic reactions reported during the first seven days were more common after mFlusiva. In the solicited safety subset, 75.7% of mFlusiva recipients and 46.7% of comparator recipients reported at least one solicited reaction.
Grade 3 or higher systemic reactions were reported by 5.5% in the mFlusiva group and 0.9% in the comparator group. Solicited reactions included injection-site pain, fatigue, headache, muscle pain, joint pain, chills, fever and nausea or vomiting.
The broader safety set included 40,703 participants with a median follow-up of 184 days. Unsolicited adverse events through 28 days occurred in 5.9% of mFlusiva recipients and 5.7% of comparator recipients. Serious adverse events occurred in 2.2% and 1.9%, respectively; investigators classified fewer than 0.1% in either group as related to vaccination.
FDA's review did not identify a major safety deficiency. That conclusion must coexist with the higher short-term reactogenicity rather than erase it. A benefit-risk account should state both findings and continue surveillance if the vaccine is authorised.
A Unanimous Vote Is Still Not the Final Decision
The committee meeting was FDA's first review of a new vaccine application since 2023. The application had also followed a February dispute in which the agency initially declined to file it, then agreed to review a split pathway addressing the comparator question for older adults.
That history is relevant to the regulatory design, but it is not evidence that either the vaccine or its critics won a political contest. The decision rests on defined efficacy, immunogenicity and safety evidence, followed by FDA's benefit-risk judgment and, for accelerated approval, a study capable of confirming clinical benefit.
The hard conclusion is procedural. A 9-0 vote deserves an exact headline, not a victory speech: advisers found the submitted evidence sufficient to recommend two age-specific pathways, one of which still depends on post-approval confirmation. FDA remained responsible for the final decision.
Public trust is not restored by calling the science clean and opponents corrupt. It is earned by publishing the denominators, naming the active comparators, separating short-term reactions from serious events and saying what remains uncertain. If mFlusiva is approved, those same standards should govern its label, recommendations and phase 4 results.